Cofoe Medical Technology Co.,Ltd. (SHE:301087)
China · Delayed Price · Currency is CNY 56.23
-0.06 (-0.11%)
At close: Mar 31, 2026
Cofoe Medical Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,252 | 2,842 | 2,706 | 2,869 | 2,129 |
Other Revenue | 135.86 | 141.38 | 148.02 | 108.05 | 146.74 |
| 3,387 | 2,983 | 2,854 | 2,977 | 2,276 | |
Revenue Growth (YoY) | 13.56% | 4.53% | -4.14% | 30.82% | -4.19% |
Cost of Revenue | 1,619 | 1,468 | 1,670 | 1,839 | 1,296 |
Gross Profit | 1,768 | 1,515 | 1,184 | 1,137 | 979.57 |
Selling, General & Admin | 1,331 | 1,095 | 851.63 | 740.79 | 471.08 |
Research & Development | 87.28 | 96.41 | 114.33 | 118.42 | 70.59 |
Other Operating Expenses | 15.6 | 9.25 | 8.18 | 12.65 | 6.24 |
Operating Expenses | 1,434 | 1,206 | 973.55 | 886.23 | 558.69 |
Operating Income | 334.51 | 309.35 | 210.31 | 251.23 | 420.89 |
Interest Expense | -16.07 | -17.91 | -13.5 | -10.85 | -6.81 |
Interest & Investment Income | 42.27 | 54.71 | 82.02 | 102.64 | 14.41 |
Currency Exchange Gain (Loss) | -4.14 | 0.52 | 0.16 | 0.36 | -0.19 |
Other Non Operating Income (Expenses) | -4.67 | -1.9 | -3.27 | -2.49 | -0.44 |
EBT Excluding Unusual Items | 351.91 | 344.78 | 275.71 | 340.89 | 427.86 |
Impairment of Goodwill | - | - | - | -0.15 | - |
Gain (Loss) on Sale of Investments | 49.84 | 9.4 | -1.56 | 4.4 | 6.02 |
Gain (Loss) on Sale of Assets | -1.37 | 5.88 | 4.59 | 6.47 | 0.14 |
Asset Writedown | 0.18 | -2.32 | -2.24 | -35.14 | -0.05 |
Legal Settlements | 1.45 | 2.19 | -2.41 | - | -0.16 |
Other Unusual Items | 23.83 | 12.07 | 11.61 | 17.91 | 74.51 |
Pretax Income | 425.84 | 372 | 285.71 | 334.39 | 508.33 |
Income Tax Expense | 55.53 | 59.66 | 32.84 | 32.37 | 78.74 |
Earnings From Continuing Operations | 370.32 | 312.34 | 252.87 | 302.02 | 429.59 |
Minority Interest in Earnings | 1.29 | -0.59 | 1.41 | -0.34 | -0.73 |
Net Income | 371.61 | 311.75 | 254.28 | 301.68 | 428.86 |
Net Income to Common | 371.61 | 311.75 | 254.28 | 301.68 | 428.86 |
Net Income Growth | 19.20% | 22.60% | -15.71% | -29.65% | 1.16% |
Shares Outstanding (Basic) | 204 | 204 | 205 | 208 | 165 |
Shares Outstanding (Diluted) | 205 | 206 | 205 | 208 | 165 |
Shares Change (YoY) | -0.20% | 0.46% | -1.70% | 26.56% | 5.47% |
EPS (Basic) | 1.83 | 1.53 | 1.24 | 1.45 | 2.60 |
EPS (Diluted) | 1.81 | 1.51 | 1.24 | 1.45 | 2.60 |
EPS Growth | 19.87% | 21.77% | -14.48% | -44.23% | -4.25% |
Free Cash Flow | 517.63 | 542.9 | 20.6 | -540.87 | -273.25 |
Free Cash Flow Per Share | 2.52 | 2.64 | 0.10 | -2.60 | -1.66 |
Dividend Per Share | 1.800 | 1.800 | 1.200 | 1.200 | 1.231 |
Dividend Growth | - | 50.00% | - | -2.50% | - |
Gross Margin | 52.20% | 50.79% | 41.48% | 38.21% | 43.05% |
Operating Margin | 9.88% | 10.37% | 7.37% | 8.44% | 18.50% |
Profit Margin | 10.97% | 10.45% | 8.91% | 10.13% | 18.85% |
Free Cash Flow Margin | 15.28% | 18.20% | 0.72% | -18.17% | -12.01% |
EBITDA | 448.85 | 411.86 | 293.98 | 292.34 | 449.78 |
EBITDA Margin | 13.25% | 13.81% | 10.30% | 9.82% | 19.77% |
D&A For EBITDA | 114.33 | 102.51 | 83.67 | 41.11 | 28.89 |
EBIT | 334.51 | 309.35 | 210.31 | 251.23 | 420.89 |
EBIT Margin | 9.88% | 10.37% | 7.37% | 8.44% | 18.50% |
Effective Tax Rate | 13.04% | 16.04% | 11.49% | 9.68% | 15.49% |
Revenue as Reported | 3,387 | 2,983 | 2,854 | 2,977 | 2,276 |
Advertising Expenses | 328.12 | 225.57 | 206.59 | 151.96 | 86.71 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.